Skip to main content
An official website of the United States government
Email

Fanconi Anemia Cancer Screening Study

A group of adolescents with Fanconi Anemia sitting on a jungle gym and smiling.

A group of adolescents with Fanconi Anemia.

Credit: Fanconi Cancer Foundation

Overview

The Fanconi Anemia Screening Study seeks to improve cancer screening in people with Fanconi anemia (FA), the most common Inherited Bone Marrow Failure Syndrome (IBMFS). Visit the participant website to enroll in the study.

Background & Purpose

Neelam Giri and Blanche Alter

Drs. Giri and Alter Receive FLEX Award

In February 2020, Neelam Giri and Blanche Alter received the CCR-DCEG FLEX award for their project on using metformin as cancer prevention for patients with Fanconi anemia.

People with FA have an increased risk of developing cancer at young ages. The most common cancer is squamous cell carcinoma of the head and neck area particularly of the tongue and oral mucosa followed by esophagus, and anogenital region. Early detection of cancer may lead to early treatment and may be important to improving overall survival in people with FA.

People with FA can develop visible changes as red and white spots or other changes in their mouth that can progress to cancer. Research studies have shown that oral mouth inspection combined with non-invasive oral brushing of these visible spots in people with FA successfully detects precancerous and cancerous lesions in people with FA.

Study Team

Neelam Giri, M.D., M.B.B.S, principal investigator

Lisa J. McReynolds, M.D., Ph.D., principal investigator

Join the Study

If you're interested in joining the study, please visit the Fanconi Anemia Cancer Screening Study enrollment website, or call (240) 276-5047 for more information.

Email